EcoR1 Capital’s Vir Biotechnology VIR Stock Holding History

EcoR1 Capital’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-270,418	Closed	-$9.27M	–	67
2020 Q1	$9.27M	Buy	+270,418	New	+$7.27M	0.97%	27

Other funds holding VIR

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.28B AUM 16.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

EcoR1 Capital's VIR Position: Q2 2020 in Review

EcoR1 Capital sold out of Vir Biotechnology (VIR) in Q2 2020, closing a stake of 270,418 shares — an estimated $9.27M sold.

EcoR1 Capital first reported a position in VIR in Q1 2020 and held it in 1 quarter. The position peaked at $9.27M in Q1 2020. 112 funds tracked by Wall St. Rank hold VIR as of Q2 2020.

EcoR1 Capital reported no remaining Vir Biotechnology position as of Q2 2020 after selling out during the quarter.
EcoR1 Capital sold 270,418 Vir Biotechnology shares in Q2 2020, an estimated $9.27M.
EcoR1 Capital first reported a position in Vir Biotechnology in Q1 2020 and held it in 1 quarter.
EcoR1 Capital's Vir Biotechnology position peaked at $9.27M in Q1 2020.
112 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2020.

Based on EcoR1 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.